These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 21574976)
1. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Kim JH; Kim YH; Kim MR; Kim SC Br J Dermatol; 2011 Sep; 165(3):646-51. PubMed ID: 21574976 [TBL] [Abstract][Full Text] [Related]
2. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. Cho HH; Jin SP; Chung JH J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542 [TBL] [Abstract][Full Text] [Related]
3. Low-dose rituximab is effective in pemphigus. Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609 [TBL] [Abstract][Full Text] [Related]
4. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765 [TBL] [Abstract][Full Text] [Related]
5. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. Leshem YA; Hodak E; David M; Anhalt GJ; Mimouni D J Am Acad Dermatol; 2013 Mar; 68(3):404-11. PubMed ID: 23044076 [TBL] [Abstract][Full Text] [Related]
6. A single cycle of rituximab for the treatment of severe pemphigus. Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130 [TBL] [Abstract][Full Text] [Related]
7. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Faurschou A; Gniadecki R Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336 [TBL] [Abstract][Full Text] [Related]
8. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients. Matsukura S; Knowles SR; Walsh S; Shear NH Arch Dermatol; 2012 Jun; 148(6):734-9. PubMed ID: 22351790 [TBL] [Abstract][Full Text] [Related]
9. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997 [TBL] [Abstract][Full Text] [Related]
10. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402 [TBL] [Abstract][Full Text] [Related]
11. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus. Londhe PJ; Kalyanpad Y; Khopkar US Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353 [TBL] [Abstract][Full Text] [Related]
12. Durable remission of pemphigus with a fixed-dose rituximab protocol. Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab treatment in Indian pemphigus patients. Kanwar AJ; Tsuruta D; Vinay K; Koga H; Ishii N; Dainichi T; Hashimoto T J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e17-23. PubMed ID: 22176540 [TBL] [Abstract][Full Text] [Related]
14. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. Reguiai Z; Tabary T; Maizières M; Bernard P J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417 [TBL] [Abstract][Full Text] [Related]
16. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243 [TBL] [Abstract][Full Text] [Related]
17. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. Barrera MV; Mendiola MV; Bosch RJ; Herrera E J Dermatolog Treat; 2007; 18(5):312-4. PubMed ID: 17852643 [TBL] [Abstract][Full Text] [Related]
18. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210 [TBL] [Abstract][Full Text] [Related]
19. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. Ahmed AR; Spigelman Z; Cavacini LA; Posner MR N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638 [TBL] [Abstract][Full Text] [Related]
20. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. El Tal AK; Posner MR; Spigelman Z; Ahmed AR J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]